Prof. Humaid Al Shamsi
MD (HON), MRCP (UK), FRCP (C), FACP
Prof. Humaid Alshamsi is a Medical Oncologist possessing more than 18 years of experience. After completing graduation from Cork University, Ireland, he pursued his internal medicine residency training at McMaster University in Canada followed by a fellowship in medical oncology in 2011 In 2013, he completed a subspecialty combined fellowship in gastrointestinal and Palliative oncology. He is the president of Emirates Oncology Society. Prof. Al Shamsi has extensive clinical and research experience in solid malignancies and he is a string advocate for palliative care in UAE.
Prof. Bradley Monk
M.D., F.A.C.O.G., F.A.C.S
Bradley J. Monk is a Gynaecologic Oncologist, academician
and researcher. He is a Professor on the Clinical Scholar Track
in the Department of Obstetrics and Gynecology at the
University of Arizona College of Medicine in Phoenix, Arizona,
as well as at the Creighton University School of Medicine in
Omaha, Nebraska. He also serves as Director of the Division
of Gynecologic Oncology at the St. Joseph’s Hospital and
Medical Center in Phoenix.
Prof. Monk has authored and co-authored over 300 peer-reviewed publications and has focused his research on
gynecologic surgery-complex, cervical cancer, ovarian cancer,
and other gynecologic cancers. He has received the Ernst
Wertheim Award for his research in cervical cancer. Monk is a
fellow of the American Society of Clinical Oncology and the
Society of Gynecologic Oncology. He is on the board of
directors for the GOG Foundation. He is an Associate Editor
for Annals of Oncology.
Prof. Gerald Prager
Internist, Hematologist and Oncologist
Head of the CRC -Unit, and MoDiTO -Platform, Austria
Prof. Gerald Prager is an Associate Professor of the Medicine Board
Certified for Internal Medicine and Board Certified for Hematology
and Medical Oncology.
He completed postdoctoral training at the University of California,
San Diego (UCSD, USA). He was a Visiting Professor at the Norris
Cancer Center, University of Southern California (USC) in Los Angeles
(USA) in 2011. In 2013 Prof. Prager became the Director of the
Gastrointestinal Cancer Program of the Department of Medical
Oncology at the Medical University of Vienna and Comprehensive
Cancer Center Vienna. Furthermore, he leads the Unit for Precision
Medicine in Cancer.
The main research interest of Dr. Prager’s lab is translational
research and (tumor-) angiogenesis. His work is honored by 20
international awards and has resulted in publications in international
highly renowned journals.
Prof. Prager is a member of the Scientific Committee of the European
Society of Medical Oncology (ESMO).
Prof. Guiseppe Curigliano
Prof. Giuseppe Curigliano, MD Ph.D., is an Associate Professor of
Medical Oncology at the University of Milano and the Head of the
Division of Early Drug Development at the European Institute of
Oncology, Italy. He is a clinician and researcher specialising in early
drug development for patients with solid tumors with a special
commitment to breast cancer.
He was awarded the first ESO Umberto Veronesi Award in Vienna and with the Fellowship of the European Academy of Cancer Sciences in Paris.
He has contributed to over 390 peer-reviewed publications.
Prof. Manuela Schmidinger
Associate Professor of Medicine
Medical Oncologist-Department of Urology
Medical University of Vienna, Austria
Manuela Schmidinger is Professor of Medicine and specialises in Internal Medicine, Medical Oncology and Intensive Care Medicine. She is currently a Senior Physician in the Department of Urology, and the Programme Director for RCC at the Medical University of Vienna, Vienna, Austria, leading the research programme in the field of kidney cancer and the care of patients with RCC. Her research interests include prognostic factors and treatment in RCC, checkpoint inhibitors, tyrosine kinase inhibitor-related side effects, and strategies to achieve long-term survival in metastatic RCC.
Professor Schmidinger is the author or co-author of more than 100 articles in peer-reviewed journals, including Annals of Oncology, British Journal of Cancer, Journal of Clinical Oncology, Leukaemia
& Lymphoma and New England Journal of Medicine. She is also a co-author of the European Guidelines for Kidney Cancer
Treatment and the author or co-author of four books in the field of immunology and oncology, including a recent textbook on
targeted agents in kidney cancer.
Prof. Nagi El Saghir
Prof. Naji is Head of the Division of Hematology-Oncology, Department of Internal Medicine The Director, Breast Center of Excellence, Naef K. Basile Cancer Institute (NKBCI)
American University of Beirut Medical Center (AUBMC)
President. Lebanese Breast Cancer Foundation (LBCF)
His professional services expand to include Lebanon, the Middle East and worldwide. He serves on many several committees with the Ministry of Public Health in Lebanon, European Society for
Medical Oncology (ESMO) and the American Society of Medical
Oncology (ASCO), including ESMO Developing Countries Task
Force and International Committee.
Prof. Nagi El Saghir has over 150 publications in peer-reviewed
journals and textbooks, hundreds of abstracts CME lectures at
International, Regional and Lebanese meetings. His research is
focused on breast cancer and young women, BRCA mutations,
awareness and early detection, breast cancer management.
Prof. Nicholas James
Prof. James has degrees in medicine and immunology from the
The University of London and a Ph.D. from Imperial College in cell
cycle biology. He undertook postgraduate training in London,
Brussels and Tokyo and is a Fellow of the Royal Colleges of
Radiology and Physicians.
Prof. Nuhad Ibrahim
Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer
Center, Houston, TX Research Interests: vaccine in breast cancer, breast geriatric oncology, treatment of resistant breast cancer. Prof. Ibrahim is a practicing Hematologist & Oncologist in Houston, Texas, US. He graduated from the University of Baghdad A1-Kindy College of Medicine. He completed a residency at University of Texas Health Science Center.
Prof. Ibrahim also specializes in Internal Medicine an Oncology. He currently practices at MD Anderson Cancer Center. He is board certified in Internal Medicine and Medical Oncology and was honored with Master of American College of Ethical Physicians, American College of Ethical Physicians and Award Doctors in America.
Prof. Robert Wolff
Dr. Wolff is a Professor of Medicine in the Department of GI
Medical Oncology at MD Anderson Cancer Center. He is also the
Deputy Division Head, Clinical and Educational Affairs in the
Division of Cancer Medicine.
Dr. Wolff graduated from Albany Medical College in Albany, New
York and completed his residency and fellowship training in
Hematology/Oncology at Duke University Medical Center. He
joined the faculty of MD Anderson Cancer Center in 1997, where
his research focused on the treatment of pancreatic cancer.
Prof. Solange Peters
Prof. Solange Peters, MD-PhD, achieved her MD from the Medical School at the University of Lausanne following this she
attended the Microbiology Institute at the University of Lausanne until concluding with an MD-PhD thesis on new HIV drug-resistance mechanisms.
Prof. Peters did her residency in Internal Medicine, followed by a Fellowship at the Multidisciplinary Oncology Centre at the
University Hospital of Lausanne. In September 2006, she sat the ESMO Examination in Oncology and was awarded the ESMO Best European Exam result.
Prof. Peters received the title of Lausanne University Private Docent (PD-MER) and was appointed Professor and Head of Medical Oncology at the Faculty of Biology and Medicine in Lausanne.
Prof. Tarek Oweidah
Prof. Tarek Owaidah currently works as a professor & consultant
Hematologist in the department of Pathology and lab medicine,
King Faisal Specialist Hospital and Research Center, Mazar, Saudi Arabia.
Prof. Tarek Owaidah’s current research interest focused on
pathology, Biostatistics, Epidemiology.
Prof. Toni Choueiri
Prof. Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Director of the Lank
Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including
combinations) and prognostic factors in advanced renal cell carcinoma (RCC). Choueiri also co-established the International metastatic database Consortium with Daniel Heng.
His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.
Dr. Antonio Passaro
Division of Thoracic Oncology,
European Institute of Oncology IRCCS, Italy
Dr Antonio Passaro is a Consultant Medical Oncologist at European Institute of Oncology, Milan, Italy. He is a specialist in lung cancer and with focus on predictive biomarkers, target agents and immunotherapy.
Dr Passaro graduated with honor from Sapienza University of Rome, completed his medical training in 2008 and gained a PhD in Molecular Medicine from the same University of Rome. He was awarded “Calabresi Foundation” for the Best Young Oncologist publication of the year in 2012 and the MiTHO (Master in Thoracic
Oncology) award in 2013. Other prizes include the Italian Association of Medical Oncology Prize for Lung Cancer in 2013.
He completed specialist training at European Institute of Oncology in Milan and appointed a Consultant in 2018. Dr Antonio Passaro is an active member of the European Society of Medical Oncology (ESMO), being a faculty member for the Lung and other Thoracic Tumours faculty group and a member of the Magnitude Clinical Benefit Scale (MCBS) Working Group In AIOM. Dr. Passaro is the extensor of lung cancer guidelines.
In 2018, he was selected and awarded for the ESMO Leadership Generation Programme. Dr. Passaro has been involved in several national and international specialist groups. He is an author of many peer-reviewed publications and is actively involved in clinical trials and translational research. He has led and been a co-applicant of successful grant applications. His research interests include Dr. Passaro’s is dedicated to improving cancer care and addressing the needs of individual patients, that remains the forefront of his philosophy of care. His research interests focus on the development of new targets and related therapeutics and immunotherapy o, as well as preclinical modeling and clinical research in lung cancer. He is an active supporter and connoisseur of Social Media in healthcare/oncology for which he has carried out national and international in-depth reports and workshops.
Dr. Elena Elimova
Dr. Elena Elimova is an Assistant Professor within the Department of Medicine, Division of Medical Oncology At the University of Toronto. she is board certified in internal medicine and medical oncology. After completing her undergraduate studies and Masters of Science in Biochemistry at Queen’s University, she earned her medical degree from the Memorial University of Newfoundland, Canada.
She completed her internship and residency in internal medicine at the University of Ottawa School of Medicine and a clinical fellowship in medical oncology at the University of Toronto, Canada, and subsequently a GI Medical Oncology Fellowship at the MD Anderson Cancer Center
Internationally she is a member of the National Cancer Institute Esophagogastric steering task force.
Dr. Enriquita Felip
Dr. Enriqueta Felip has been the Head of the Lung Cancer Unit, Oncology Department at Vall d’Hebron University
Hospital. Dr. Felip received her medical degree from The Autonomous University of Barcelona where she also completed her studies for a Ph.D. in Medical Oncology.
Dr. Felip is the Head of the Thoracic Cancer Unit and is responsible for all Lung Cancer trials at Vall d’Hebron University Hospital.
Research lines of the Lung Cancer Unit include the optimisation of chemotherapy in early-stage disease, and evaluation of new.
Dr. Felip is also an Associate Professor of Medical Oncology
(School of Medicine) at the Autonomous University of Barcelona.
Dr. Francesco Grossi
Director of the Division of Medical Oncology Associate Professor at the University of Insubria, Italy
Professor Francesco Grossi is currently Director of the Division of Medical Oncology and Associate Professor at the University of Insubria in Varese, Italy.
His major interests, apart from lung cancer and mesothelioma, are translational research in thoracic oncology and new drug development. He is the principal investigator and coordinator in international and national clinical trials and project leader in translational studies.
He received his medical degree from the University of Genova in Italy and served an internship and residency in biochemistry and oncology in the same University. Prior to this current position, he was Deputy Head at the Division of Clinical Oncology at the University of Udine (1999-2003), Director of the Lung Cancer Unit and Lung Cancer Translational Research Lab and Chairman of the Disease Management Team Lung Cancer at the National Institute for Cancer Research in Genova, Italy (2003-2018) and Director of the Division of Medical Oncology at the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milano, Italy (2018-2021).
In 1997, he received the American Society of Clinical Oncology (ASCO) merit award and in the same year the AIOM (Italian Association of Medical Oncology) merit award. From 2008 to 2012 he was a Member of the National Committee of Cancer Prevention at the Ministry of Labor, Health and Social Policy.
He is an active member of several international societies including ASCO, ESMO and IASLC. He has authored more than 250 articles indexed in PubMed. He has been invited to give lectures in numerous national and international meetings.
Dr. Hampig Kourie
Dr. Hampig Kourie gained his Medical Doctor degree from the faculty of medicine of Saint Joseph University in Beirut Lebanon in 2010. He started his fellowship in Hôtel-Dieu de France, University
Hospital in Beirut, Lebanon and since 2014 he is a medical oncology fellow at the Jules Bordet Institute in Brussels, Belgium.
He is an active member of the European Society for Medical Oncology (ESMO) and in 2016 he was nominated Member of the
ESMO Membership Committee. He has published more than 60 peer-reviewed articles.
Dr. Hooman Soleymani Majd
Consultant Gynaecological Oncology Surgeon & Senior Clinical Lecturer.
Dr. Hooman is a sub-specialist in gynaecology oncology, working as a consultant at the Churchill Cancer centre since 2016. He is a BSCCP accredited colposcopist and trainer. I have a special
interest in developing new surgical techniques in ultra-radical surgery for advanced ovarian cancer and radical pelvic
exenteration operations. His skill set includes upper abdominal surgery, liver mobilisation and diaphragmatic reconstruction.
Dr. Hooman has extensive expertise in treating patients with severe Placenta Accreta Spectrum (PAS). He is a founding
member and surgical lead for the OxPAT group. He is also a member of the Oxford Sarcoma team.
He is actively involved in teaching registrars/fellows and medical
students from Oxford University.
Dr. Roula Al Mufti
Dr. Roula gratuated in Medical college, King Abdulaziz University, Jeddah. She joined Medical Oncology team department as associate consultant in princess Nora Oncology center, King Abdulaziz Medical city , Jeddah ,Saudi Arabia from February 2017.
Dr. Roula did lots of lectures and workshops on Gynecology and breast oncology, Paris & Lyon, as well as lectures on fundamentals of Oncology, Institute Gustave Roussy.
Her Publications: Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review,
Journal of the National Cancer Institute, 2012 (co-author) A critical review of the analytical approaches for circulating tumor
biomarker kinetics during treatment, Annals of Oncology 2014 (first author)
Dr. Omalkhair Abulkhair
Dr. Abulkhair is a Consultant in the Division of Adult Medical, Department of Oncology in Ministry of National Guard Health Affairs – Saudi Arabia and Assistant Professor at the King Saud bin Abdulaziz University for Health Sciences.
She is the Course Director of major symposia in the department which is the “Middle East Best of San Antonio Breast Cancer Symposium” and “Cancer Prevention and Early Detection Symposium”. She was also selected as the Chairman for MENA-NCCN Guidelines Committee for Breast Cancer.
has written numerous publications and abstracts which leads to receiving three Dr. Abulkhair awards for best abstract.
Dr. Abdul Rahman El Kinge
Dr. El Kinge completed his postdoctoral studies in Internal Medicine and fellowship in Hematology / Oncology at the American University of Beirut Medical Center. He was trained in Breast Cancer in MD Anderson Cancer Center and he is certified by the European Society of Medical Oncology.
Dr. El Kinge is on the editorial board and a reviewer in multiple international medical journals. He is a Fellow of the American College of Physicians, and a member of local and international Hematology and Oncology Societies. He has multiple peer-reviewed publications.
He is currently Head of the Department of Hematology / Medical Oncology on NMC Royal Sharjah
Dr. Amine Abyad
Oncologist, Burjeel Cancer Institute, UAE.
Dr Amin Abyad earned his medical degree from Beirut Arab University in 2014 followed by internal medicine and fellowship in hematology and medical oncolcogy from Makassed General
Hospital Beirut: Lebanon’s first-ever Hematology and Bone Marrow
He is highly interested in malignant Hematology and Clinical Research.
He published multiple articles in hematology Bone Marrow
Transplant and infection.
He joined Burjeel Cancer Institute in July 2021
Dr. Ahmed Al Rustamani
Consultant Hematologist at the American & Canadian Boards
of Internal Medicine and Hematologist in the UAE
Dr. Aydah al Awadhi
Consultant Medical Oncologist
Tawam Hospital, UAE
EOS Scientific Committee Chairperson
Dr. Aydah Al Awadhi graduated from The United Arab
Emirates University in Al-Ain, completed her residency in Saint
Vincent hospital affiliated with University of Massachusetts in
Worcester, MA and recently completed fellowship training in
Hematology/Oncology at MD Anderson Cancer Center. While
at MD Anderson Cancer Center, Dr. Al-Awadhi published
number of peer review articles in international journals and
presented abstracts mainly in breast cancer presented in US
national meetings. She also wrote multiple book chapters
mainly in breast cancer.
Dr. Aqeel Saleem
Dr. Aqeel Joined Tawam / Al Ain Hospitals as Infectious Diseases Consultant. He gratuated Residency in Internal Medicine, from the University of Pittsburgh, Pennsylvania 2002 Infectious Diseases fellowship from University of West Virginia 2002-2004 Practiced Infectious Diseases at USA from 2004-2008 Director Infectious Diseases fellowship Chair Antimicrobial Stewardship at SEHA from 2017-2019 Chair Infection control 2017 – to date Published articles – peer reviewed Journals
Dr. Bassam Odeh
Dr. Bassam Odeh graduated from Damascus University He did his training and practice in internal medicine at Damascus university hospitals before he moved to the UK. Dr. Bassam have been working in the last 14 years in the field of hematopathology and blood transfusion service. This period was distributed equally between the UK and UAE. Dr. Bassam’s practice and experience in the UK was mixed between clinical haematology and haematopathology.
Dr. Dalia Al Shorbagy
Consultant Medical Oncology,
Dr. Dalia El Shorbagy is a Consultant Medical Oncologist at
Dubai Health Authority since 2009. Dr. Shorbagy is an Assistant Professor in the Clinical Oncology University Hospital, Egypt.
Dr. Dina Hamza
Consultant Medical Oncology,
Dr. Dina is a senior clinical oncologist in Dubai. She is also a consultant of clinical oncology, MOH, Egypt and a Postgraduate Clinical Researcher, ULM University, Germany.
Dr. Dina earned a bachelor degree in medical school with high honors at Cairo University, Egypt. She therefore completed her medical training at the University of Medicine, El Kasr Al Aini.
She pursued her passion for oncology by completing a master degree at the National Cancer Institute and served as a chief
clinical oncologist.She has published journal articles on various topics, lectured to physician and non-physician groups on advances in cancer treatment.
Dr. Deborah Mukherji
Dr. Mukherji completed her advanced specialty training in Medical Oncology at Guys and St Thomas’ NHS Foundation
Trust, London UK and was awarded Post-Graduate Diploma in Oncology from the Institute of Cancer Research University
of London. On completion of her advanced specialty training, Dr. Mukherji joined the Royal Marsden Hospital London where
she worked with Professor Johann De Bono specializing in clinical research and drug development with a focus on prostate cancer.
Dr. Mukherji co-chairs the Advanced Prostate Cancer Consensus Conference Middle East Satellite Meeting and is an active member of many international medical societies.
Dr. Mukherji has over 130 peer-reviewed publications with
over 2500 citations.
Dr. Diaaeddine Trad
Dr. Diaaeddine Trad completed his residency in internal medicine in 1992 and his fellowship in hematology and
oncology in 1994 at the American University of Beirut Medical Center, Lebanon. He joined Tawam Hospital in 1995. Dr. Trad has a special interest in the management of head and neck cancer and other solid tumors.
He has participated in many local and international clinical trials and has many publications. He has been a faculty member of many of the local and regional oncology conferences.
Dr. Dorai Ramanathan
MBBS, MRCP(UK), FRCR(UK), CCT(UK)
Consultant Medical Oncologist
Al Zahra Hospital
Dr. Dorai is a highly qualified Oncologist from the UK with over 13 years’ experience in managing adult cancer patients. His expertise is in Chemotherapy and Radiotherapy for all adult solid tumors. His sites of special interest are breast, lung, gynaecological, and colon cancer.
Dr. Dorai has experience in prescribing chemotherapy, targeted treatment and immunotherapy. He is also a qualified radiation oncologist from UK, and is an expert in delivering treatment in techniques such as IMRT (Intensity Modulated Radiotherapy) and IGRT (Image Guided Radiotherapy).
Dr. Emad Dawoud
Dr. Emad Anwar Dawoud is a consultant Medical Oncologist in the Oncology department at Tawam Hospital since 2014.
He completed his MD, PhD in clinical oncology at the Federation of Royal Colleague of Physician of United Kingdom in 2012.
Dr. Dawoud graduated from Al Azhar University in Cairo in 1997 and was assigned as lecturer of clinical oncology at the same university in 2010. He been principal investigator and co-investigator for more than 50 clinical trials and he published the abstracts in peer reviewed journals.
Dr. Dawoud is member in various associations such as ASCO,
ESMO & ESTRO.
Dr. Fathi Azribi
Consultant Medical Oncology,
Division Chief, Tawam Hospital,
Dr. Azribi trained in the teaching hospitals of Tripoli, Libya; where he completed his general medical training. He moved to the UK, where he completed specialty training in Medical Oncology at Newcastle upon Tyne hospitals and obtained a Certificate of Completion of Training in Medical Oncology . After he started as a consultant medical oncologist in UK.
He worked as a consultant Medical Oncologist at Tawam Hospital, and currently he is the Chief of Medical Oncology Division.
He has extensive medical knowledge and experience in medical oncology. His main interest is in thoracic, breast, gynaecological and gastrointestinal malignancies with expertise in all types of systemic treatments including chemotherapy, immunotherapy, hormonal and targeted therapy.
Dr. Falah Al Khatib
Dr. Al Khatib gratuated from the faculty of medicine, Ain
Shamis University. He completed his training and residency in
specialty to radiotherapy and had his DMRT and obtained his
fellowship FFRRCSI in 1984.
Dr. Al Khatib worked as a consultant and chief of radiotherapy
at Tawam Hospital. He helped to establish Tawam Hospital as
the main Cancer Center in the UAE and the region.
In 2011 Dr Al Khatib started working as Consultant Clinical
Oncologist at Mediclinic City Hospital, Dubai UAE.
Dr. Al Khatib is the Vice President of The Emirates Oncology
Dr. Hassan Ghazal
Consultant Oncologist & Hematologist
King’s College Hospital
Dr.Ghazal is an American board-certified Consultant Medical
Oncologist and a Consultant Clinical Hematologist offering more
than 3 decades of clinical experience.
Dr. Ghazal, after completing his basic medical education in the
American University of Beirut, moved to the US for his residency
program in Internal Medicine where he joined several hospitals
and got his US board certification in Internal Medicine, Medical
Oncology and in Hematology.
Dr. Ghazal is a member of various clinical societies and has many
publications and abstracts in his credit, in peer-reviewed journals
and there are many international recognitions and accolades in
Dr. Hassan Ghazal has been involved in numerous clinical trials,
nearly 100, in the US, serving as Principal Investigator, for over 25
years, and enrolled hundreds of patients in these trials.
Dr. Hassan Jaafar
Consultant Medical Oncology
Sheikh Khalifa Speciality Hospital
Dr. Jaafar is a medical oncology consultant in SKSH. He
completed his fellowship in Hematology/Oncology and been
certified as a medical hematologist/Oncologist from the
American University of Beirut Medical Center, Lebanon.
He is the author and co-author of more than 50 peer-viewed
papers and abstracts. He is involved in more than 6 ongoing
phase III trials regional and international and he is a member of
the GOG (Gulf Oncology Group) that conducted 2 phase II trials.
Dr. Hesham Abdullah
Dr. Hesham A. Abdullah, MD, is Senior Vice President and Global Head of Oncology Development at GSK, where he oversees the end-to-end strategic development and delivery of GSK’s
oncology clinical-stage portfolio. Dr. Hesham is a proven global drug developer whose leadership and oversight responsibilities have led to multiple targeted oncology products and companion
diagnostic approvals, including Iressa®,Lynparza™, Tagrisso®,
Imfinzi™, Calquence®, Lumoxiti™, Zejula®, Blenrep and Jemperli, while setting numerous drug development precedents along the way.
Dr. Hesham is a seasoned researcher, clinician, and senior executive with wide-ranging experiences in biopharmaceutical research & development, including small and large molecules, spanning early and late stages of drug development, in both solid & hematological malignancies.
Dr. Khaled Mussalem
Dr. Maroun Khoury
Consultant Medical Oncologist,
Director of Cancer Care Center,
American Hospital Dubai, UAE
Dr. Maroun El Khoury completed his basic medical training from Saint Joseph University School of Medicine Beirut, Lebanon in 1999. He is also a member of the American Society of Clinical Oncology, American Society of Hematology and American Academy of Pain Management. Dr. Maroun Khoury is American Board certified in Oncology, Hematology and Internal Medicine.
He is the Director of Cancer Care Center and the President of the Medical Staff at the American Hospital Dubai.
Dr. Nadia Abdel Wahed
Dr. Nadia is Syrian Board certified in medical oncology. She completed her medical degree from Alfurat college in Syria. She completed medical oncology residence and a master’s degree in oncology at Damascus University in Syria.
She worked as a specialist in solid tumors at Albirouni University Hospital and Wecare specialty center in Damascus, Syria.
Dr. Norbert Drier
Medical Oncologist Consultant Oncology at Burjeel Hospital, UAE
Dr. Saeed Raﬁi
Consultant Medical Oncologist
Saudi German Hospital
EOS General Secretary
Dr. Rafii was trained in Internal Medicine in Leicester in the UK followed by a work experience in many prestigious UK cancer Hospitals
Dr. Rafii holds a PhD and a postdoctoral fellowship in molecular cancer genetics specializing in DNA repair targeting.
He has been Chief or Principal investigators on over 100 early or late phase clinical trials, have published over 45 manuscripts in prestigious oncology journals and have presented in international oncology conferences. He won AACR Young Investigators Award for work on DNA repair and breast cancer association.
He was elected as a fellow of the Royal College of Physicians in 2018 in recognition of his work in cancer research.
Dr. Sonia Ostman
Consultant Medical Oncology, Cleveland, UAE
Dr. Sonia Otsmane is a Consultant Medical Oncologist-Hematologist since 2004. She graduated from the Central Faculty of Medicine Algiers in 1994. She worked as Medical Oncologist-Hematologist at Tawam hospital in affiliation with John Hopkins from 2006 till 2013.
In December 2019, she was appointed as the Medical Oncologist-Hematologist consultant at Sheikh Shakhbout Medical City, Abu Dhabi in affiliation with Mayo Clinic. Currently she is operating at Cleveland Clinic Abu Dhabi.
Dr. Ostmane published several abstracts and articles in peer viewed journals and participated in many local and international meetings.
Dr. Syed Hammad Tirmazy
Consultant Clinical Oncologist
Head of Oncology
Dubai Hospital, DHA
EOS Cultural Committee Chairperson
Dr. Syed Hammad Tirmazy has substantive experience in managing adult solid cancers and has been involved in multiple
international clinical trials. Before moving to Dubai in 2016, he was in the UK where he completed his Internal Medicine training and MRCP and later on, worked in internationally renowned oncology centers in the UK including Queen Elizabeth Hospital, Birmingham. He completed Masters in Clinical Oncology from University of Birmingham, FRCR Clinical Oncology from RCR London and has CCT in Clinical Oncology. He also attained FRCP Glasgow.
Dr. Urfan Ul Haq
Consultant Medical Oncologist
Dr. Urfan completed his graduation (MBBS) from the Ayub Medical College and was awarded the Gold Medal for his academic
excellence. He was awarded a Fellowship from the Royal College of Physicians and Surgeons (FCPS) in Pakistan. In 2002 Dr. Urfan became a Member of the Royal College of Physicians (MRCP), UK. Later he successfully completed his European Society of Medical Oncology (ESMO) certification. Additionally, he did UK
Medical Oncology subspecialty certification.
He moved to the UAE where he practiced at one of top government hospitals in Abu Dhabi.
Dr. Urfan was also the co-director of the Arab Board Residency programs for postgraduate training of physicians. He is also an instructor for Advanced Life Support (ALS) and Advanced Cardiac Life Support (ACLS) He is a member of many societies including the European Society of Medical Oncology.